Psychedelics – News and Features

An analysis of Maryland ketamine advertisers has suggested that their websites and marketing materials are awash with false and misleading claims about the drug’s addictiveness, side effects and approval status.

Most people who have pulled an all-nighter are too familiar with that “tired and wired” feeling. The body is physically exhausted, the brain feels loopy and almost giddy. Now, neurobiologists are the first to uncover what produces this effect.

Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.

Your favorite music might be good for more than a workout soundtrack or late-night listening session, suggests a new study. The research suggests that individuals’ most-loved music could reduce feelings of pain compared to relaxing stock music.

Patients with treatment-resistant depression are missing out on potentially life-changing treatment with ketamine because systemic barriers in the public health system have made it unaffordable.

DNA analysis of mummified poop reveals two pre-Columbian Caribbean cultures ate a wide variety of plants, like maize, sweet potato, and peanuts—and tobacco and cotton traces were detected too, according to a study.

In recent years, interest in psychedelic substances and their possible benefit in the treatment of psychiatric illnesses has been greatly revived.

Ketamine is increasingly used as an antidepressant. A new clinical trial suggests the drug's effects may be may be placebo-based. In this article, we explore what that means for the drug's rollout for ketamine and psychedelic research.

A new clinical trial has shown that ketamine nasal spray treatment in patients with treatment-resistant depression led to higher rates of remission than standard intervention with the antipsychotic drug quetiapine.

One treatment each of two psychedelic drugs lowered depression and anxiety and improved cognitive functioning in a sample of U.S. special operations forces veterans who sought care at a clinic in Mexico.